Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: EC:3.4.16.2 (
PCP
)
3,761
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Exposing the developing brain to the N-methyl-D-aspartate (NMDA) receptor antagonist phencyclidine (
PCP
) has been shown to cause deficits in neurobehavioral functions, particularly on learning and memory and seizure sensitivity. Besides acting as a noncompetitive NMDA antagonist,
PCP
at high doses is known to affect the dopaminergic system. The present study assessed the effect of postnatal
PCP
treatment on locomotor activity and striatal dopamine (DA) D(2) receptor. Male and female rat pups were injected intraperitoneally (i.p.) with one of three doses of
PCP
(1, 3 and 5 mg/kg) or saline from postnatal day (PD) 5 to PD 15. Control and
PCP
-treated rats were given a challenge dose of
PCP
(10 mg/kg) as adults, and their locomotor behaviors--locomotion, stereotypy and ataxia--were scored. Postnatal
PCP
treatment did not have any significant effect in either sex on any of the
PCP
-induced locomotor behavioral paradigms studied. Separate groups of male and female rats were treated daily with saline or
PCP
(5 mg/kg i.p.) from
PD 5
to PD 15 and sacrificed either as juveniles (PD 21) or adults, and D(2) receptor binding was measured in their striata. Striatal D(2) receptor density in juvenile and adult male postnatal
PCP
-treated rats did not differ from saline-treated controls. Adult female
PCP
-treated rats showed a slight but significant reduction in the maximal binding of striatal D(2) receptors. There was no effect of postnatal
PCP
on striatal D(2) receptor binding in female juvenile rats. These results support the hypothesis that blocking the developing NMDA receptor minimally affects
PCP
-induced locomotor behavior and the striatal D(2) receptor.
...
PMID:Effects of postnatal PCP treatment on locomotor behavior and striatal D2 receptor. 1266 9
The N-methyl-D-aspartate (NMDA) receptor and brain-derived neurotrophic factor (BDNF) are both known to play major roles in the normal development of the brain. We have hypothesized that the chronic blockade of NMDA with phencyclidine (
PCP
) may have a different effect on BDNF synthesis at different stages of development. In an acute experiment, rat pups and adult rats were injected with
PCP
(2.5, 5 or 10 mg/kg) at postnatal day (PD) 15 or 49, respectively. In a chronic experiment, rat pups were injected daily from
PD 5
to PD 14 with
PCP
(2.5, 5 or 10 mg/kg), while adult rats were injected daily with the same dose from PD 39 to PD 48. BDNF levels in the hippocampus, striatum and frontal cortex were determined by ELISA assay 24 hours after the last injection. Chronic
PCP
treatment of neonatal rats induced a dose-dependent decrease in BDNF in the hippocampus but not in the frontal cortex and striatum. Single injection of
PCP
to rat pups showed a slight reduction of BDNF in the hippocampus but only at higher doses. In contrast to neonatal brain, neither acute nor chronic injection of
PCP
influenced BDNF in adult brain. These findings suggest that chronic blockade of NMDA receptor in the early neonatal period has an inhibitory effect on BDNF synthesis in the hippocampus and may impair normal neurodevelopment in rat pups.
...
PMID:Different effects of chronic phencyclidine on brain-derived neurotrophic factor in neonatal and adult rat brains. 1680 Aug 25
